Abstract
Anti-John Cunningham (JCV) antibodies have been detected in approximately 50% to 60% of multiple sclerosis (MS) patients. Age, sex, and geographic location have been associated with seroprevalence differences. We describe anti-JCV antibody prevalence in the Canadian cohort of patients enrolled in the JCV Epidemiology in MS study. This cross-sectional multicenter study evaluated the effects of demographic and disease characteristics on anti-JCV antibody seroprevalence in MS patients irrespective of disease type and treatment. A single blood sample was collected for analysis of anti-JCV antibodies using a two-step enzyme-linked immunosorbent assay (ELISA). Chi-square and logistic regression tests were used to determine significance. A total of 4198 Canadian MS patients participated in the study; the overall anti-JCV antibody prevalence was 56.3% (95% confidence interval: 54.8% to 57.8%). Seroprevalence was significantly associated with age (increasing from 45% in young to 61% in those >60 years), sex, and region (p<0.0001 for age and sex; p=0.005 for region). No significant differences in anti-JCV antibody prevalence were associated with race, MS disease type and duration, or number and duration of treatments. Immunosuppressant use was associated with a higher seroprevalence rate (63.4%) compared with no immunosuppressant use (55.9%; p=0.040). Canadian MS patients had an overall anti-JCV antibody seroprevalence that was consistent with previous studies using the two-step ELISA. Significant associations of anti-JCV antibody positivity were found with age, sex, region, and immunosuppressant therapy, whereas seroprevalence was not associated with race, MS type, MS duration, or number or duration of MS treatments.
Highlights
Anti–John Cunningham (JCV) antibodies have been detected in approximately 50% to 60% of multiple sclerosis (MS) patients
The Canadian cohort of MS patients participating in the JEMS study had an overall anti-John Cunningham virus (JCV) antibody seroprevalence of 56.3%
These results are consistent with previous reports of anti-JCV antibody seroprevalence rates in MS patients receiving or considering treatment with natalizumab.[5,6,7,8,9,10,11,12]
Summary
The JEMS study was a cross-sectional, multicenter, multinational epidemiological study (NCT01185717).[14]. The study involved one visit, in which participating sites’ personnel collected patient information (birth date, sex, and race) and asked patients to list all therapies they received for MS treatment, including last dose date and treatment duration. Patients with anti-JCV antibody test results and demographic data were included in the analyses. The prevalence of anti-JCV antibodies was described by age, sex, race, region, type of MS, duration of MS, and treatment status using descriptive statistics. Chi-square test and logistic regression model (univariate and multivariate analyses) were used to compare anti-JCV antibody prevalence by geographic and demographic factors, as well as MS type, disease duration, and treatment status
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
